AI biotech insitro partners with Lilly on metabolic disease drugs

If all goes ac­cord­ing to plan, in­sitro could fi­nal­ly start test­ing its first drug in clin­i­cal tri­als in 2026, eight years af­ter Daphne Koller found­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.